XML 41 R47.htm IDEA: XBRL DOCUMENT v2.4.1.9
Investment in Affiliate (Details Narrative) (USD $)
1 Months Ended 12 Months Ended 1 Months Ended
Dec. 30, 2013
Dec. 28, 2013
Dec. 01, 2014
Jan. 03, 2015
Mar. 28, 2013
Senior note to an unrelated party $ 1,250,000us-gaap_ExtinguishmentOfDebtAmount        
Remaining outstanding on the Senior Note at the date of assignment 2,275,000cdxc_NotesReductionTransactionAmount        
Legal fees 7,500us-gaap_SponsorFees        
NeutriSci Preferred shares due to an unrelated party 500,000cdxc_PreferredSharesDueToNeutrisci        
Placement agent cash fee 150,000cdxc_SponsorFees2        
NeutriSci Preferred shares due to Palladium 50,000cdxc_SponsorFeesShares        
NeutriSci [Member]          
Sale transaction value, cost recovery method   3,157,804us-gaap_ProceedsFromSaleOfOtherProductiveAssets
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cdxc_NeutriSciMember
     
Cash payment for agreement   1,000,000us-gaap_PaymentsToAcquireProductiveAssets
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cdxc_NeutriSciMember
     
Secured note   2,500,000us-gaap_ProceedsFromSecuredNotesPayable
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cdxc_NeutriSciMember
     
Convertible shares   625,000cdxc_SecuredNoteConvertibleShares
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cdxc_NeutriSciMember
     
Series I preferred shares issued   669,708us-gaap_AuctionMarketPreferredSecuritiesSharesIssued
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cdxc_NeutriSciMember
     
Series I conversion into Class A Common Shares   2,678,832cdxc_SeriesIConversionIntoClassCommonShares
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cdxc_NeutriSciMember
     
Class A common percent of deemed shares   19.00%us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cdxc_NeutriSciMember
     
Carrying value, equity investment, beginning balance   2,157,804us-gaap_EquityMethodInvestments
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cdxc_NeutriSciMember
     2,157,804us-gaap_EquityMethodInvestments
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cdxc_NeutriSciMember
Cash payment received   225,000us-gaap_ProceedsFromCollectionOfNotesReceivable
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= cdxc_NeutriSciMember
     
Series I Unrelated Party 1 [Member]          
Series I preferred shares transferred     108,676us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
/ us-gaap_EquityInterestIssuedOrIssuableByTypeAxis
= cdxc_SeriesIUnrelatedParty1Member
   
Series I Paladium [Member]          
Series I preferred shares transferred     10,868us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
/ us-gaap_EquityInterestIssuedOrIssuableByTypeAxis
= cdxc_SeriesIPaladiumMember
   
Series I Unrelated Party 2 [Member]          
Sale of preferred stock, shares     551,114us-gaap_PartnersCapitalAccountUnitsSaleOfUnits
/ us-gaap_EquityInterestIssuedOrIssuableByTypeAxis
= cdxc_SeriesIUnrelatedParty2Member
   
Proceeds from sale of preferred stock     749,515us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock
/ us-gaap_EquityInterestIssuedOrIssuableByTypeAxis
= cdxc_SeriesIUnrelatedParty2Member
   
Loss on sale of preferred stock     (24,286)us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee
/ us-gaap_EquityInterestIssuedOrIssuableByTypeAxis
= cdxc_SeriesIUnrelatedParty2Member
   
Value of preferred stock sold     773,801us-gaap_PartnersCapitalAccountSaleOfUnits
/ us-gaap_EquityInterestIssuedOrIssuableByTypeAxis
= cdxc_SeriesIUnrelatedParty2Member